Calcium magnesium phytate
Phytate (IP6, inositol hexaphosphate) is the calcium-magnesium salt of a natural plant compound found in grains, legumes, and nuts. Marketed for kidney-stone prevention, iron overload, and 'cellular detox'. The kidney-stone story has the most evidence — and it's still limited; most other claims are mechanistic or preclinical.
Quick decision guide
May help most
Adults with recurrent calcium-oxalate kidney stones whose urine phytate is documented low — under nephrologist guidance.
Common dosing range
Supplemental IP6 (calcium-magnesium phytate) is typically dosed 800–2,000 mg/day. Some kidney-stone trials used 380 mg/day phytate.
When to expect effects
Urinary phytate rises within days of supplementation. Stone-recurrence outcomes measured over months.
Watch out for
Reduces absorption of iron, zinc, and calcium from the same meal. Take well away from mineral-rich meals or supplements.
Evidence snapshot
What is it
Calcium magnesium phytate (also called calcium magnesium inositol hexaphosphate, or Cal-Mag IP6) is the calcium and magnesium salt form of phytic acid (inositol hexaphosphate, IP-6). It naturally occurs in seeds and bran and is the storage form of phosphorus and inositol in plants.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Calcium-oxalate kidney stone prevention Limited Evidence | Roughly 30–40% lower stone risk in highest vs lowest dietary phytate quartile in young women; biomarker (urinary phytate, crystallization) improvements in supplementation studies | Adults with recurrent calcium-oxalate stones and documented low urinary phytate, under nephrologist guidance | Days for urinary biomarker; months for stone-recurrence endpoints |
Antioxidant / cellular protection (mechanism) Mixed Evidence | Mechanistic iron chelation; no documented human clinical-endpoint outcome | None on current evidence | Not established |
Cancer chemoprevention Mixed Evidence | Preclinical tumor reduction in cell lines and rodents; no human-outcome trial | None on current evidence | Not established for any human cancer endpoint |
Iron overload (hereditary hemochromatosis, transfusion overload) Mixed Evidence | Mechanistic iron chelation; no clinical trial in iron-overload patients | None as monotherapy; could theoretically be adjunctive under hematologist guidance | Not established |
Calcium-oxalate kidney stone prevention
- Effect
- Roughly 30–40% lower stone risk in highest vs lowest dietary phytate quartile in young women; biomarker (urinary phytate, crystallization) improvements in supplementation studies
- Best fit
- Adults with recurrent calcium-oxalate stones and documented low urinary phytate, under nephrologist guidance
- Time
- Days for urinary biomarker; months for stone-recurrence endpoints
Antioxidant / cellular protection (mechanism)
- Effect
- Mechanistic iron chelation; no documented human clinical-endpoint outcome
- Best fit
- None on current evidence
- Time
- Not established
Cancer chemoprevention
- Effect
- Preclinical tumor reduction in cell lines and rodents; no human-outcome trial
- Best fit
- None on current evidence
- Time
- Not established for any human cancer endpoint
Iron overload (hereditary hemochromatosis, transfusion overload)
- Effect
- Mechanistic iron chelation; no clinical trial in iron-overload patients
- Best fit
- None as monotherapy; could theoretically be adjunctive under hematologist guidance
- Time
- Not established
Evidence for 4 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Calcium-oxalate kidney stone prevention
Supplement benefitPhytate strongly inhibits calcium-oxalate and calcium-phosphate crystallization in urine. Low urinary phytate is found in calcium-stone formers. Small supplementation trials show that oral IP6 raises urinary phytate and reduces crystallization markers. The Nurses' Health Studies cohort analysis found higher dietary phytate intake associated with modestly lower stone risk in younger women, though the effect wasn't significant in older women or in men. There are no large, long-duration randomized controlled trials with stone-recurrence as the primary endpoint.
Bottom line: The best-supported use, and the evidence is still moderate at best. Discuss with your nephrologist if you have recurrent calcium stones.
Antioxidant / cellular protection (mechanism)
Mechanism onlyPhytate strongly chelates free iron and other transition metals, reducing Fenton-reaction-mediated oxidative stress in vitro. This is the basis of the 'antioxidant' marketing. No human trial has measured clinical-endpoint outcomes — disease incidence, longevity, biomarker improvement at a meaningful level — from supplemental phytate as an antioxidant.
Bottom line: Real mechanism, no clinical-outcome evidence. Don't take it as a general antioxidant.
Cancer chemoprevention
Mechanism onlyShamsuddin and colleagues published a substantial preclinical body of work suggesting IP6 inhibits proliferation in colon, breast, and prostate cancer cell lines and reduces tumors in rodent models. No randomized controlled trial has tested IP6 in any human cancer indication. The mechanism (iron chelation, cell-cycle effects, immune modulation) is biologically plausible but unverified clinically.
Bottom line: Preclinical promise; no human trials. Don't use it as a cancer therapy.
Iron overload (hereditary hemochromatosis, transfusion overload)
Mechanism onlyIP6 is a strong iron chelator and has been proposed as an adjunct in iron overload conditions. Outside of dietary phytate's known ability to reduce non-heme iron absorption (a real, large effect in single-meal studies), there are no controlled trials of supplemental IP6 for iron overload. Standard treatments — therapeutic phlebotomy, deferasirox, deferoxamine — remain the evidence-based approach.
Bottom line: Mechanistic chelator. Use evidence-based iron-overload treatment, not IP6.
How it works
How to take it
What to track
Bottom line: If you're trying it for kidney stones, dose at 800–2,000 mg/day between meals, monitor iron and zinc status, and follow up with your nephrologist.
2 commercial forms
Compare the main delivery options and what they’re best suited for.
Calcium-magnesium phytate (calcium-magnesium IP6)
Standard supplement formThe mixed calcium-magnesium salt of phytic acid. The most common supplement form. Provides some elemental calcium and magnesium but mostly characterized by the IP6 anion.
Provides bioavailable IP6 in the GI tract after dissociation.
Phytic acid / sodium phytate
Free acid / sodium saltUsed in food science as an antioxidant preservative and chelator; less common in consumer supplements. Same IP6 anion as the calcium-magnesium salt.
Comparable IP6 delivery; salt counterion differs.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Iron deficiency from chronic high-dose use, especially in vegetarians, vegans, women with menstrual losses, growing children, and pregnancy. The mineral-binding effect is the most clinically relevant safety concern.
Zinc deficiency from chronic dietary or supplemental phytate, particularly in populations with marginal zinc intake.
Reduced calcium absorption when taken with calcium-containing meals or supplements. May undermine osteoporosis treatment if mistimed.
Who should avoid it
- People with diagnosed iron deficiency, iron-deficiency anemia, or risk factors (heavy menstrual periods, IBD, postpartum, vegan diet without close iron monitoring).
- Children and adolescents in growth phases — the mineral-binding effect can compromise iron and zinc nutrition.
- Patients on osteoporosis treatment relying on calcium supplementation timing.
- Pregnancy and breastfeeding — iron and zinc requirements are higher; mineral binding could compromise maternal or fetal nutrition.
Pregnancy & breastfeeding
Avoid supplemental phytate in pregnancy and breastfeeding. Iron and zinc requirements are higher in these states, and phytate's mineral-binding effect could compromise both maternal and fetal nutrition. Whole-food dietary phytate is fine and unavoidable.
Bottom line: The dominant safety issue is mineral binding. Take it well separated from meals and supplements, monitor iron and zinc status if used long-term.
Interactions
Phytate binds iron in the gut; co-administration reduces iron absorption substantially. Separate by at least 2 hours.
Similar binding mechanism reduces zinc absorption. Separate doses by at least 2 hours.
Phytate reduces calcium absorption when co-administered. Separate doses; calcium-magnesium phytate inherently provides some calcium and magnesium.
Theoretical additive iron chelation. No documented clinical issue but warrants hematologist coordination if both are used.
Food sources
| Food | Amount | %DV |
|---|---|---|
| Wheat bran | 1 oz (~700 mg phytic acid) | — |
| Almonds, raw | 1 oz (~400 mg phytic acid) | — |
| Sesame seeds | 1 oz (~1,400 mg phytic acid) | — |
| Soybeans, dry | ½ cup (~1,000 mg phytic acid) | — |
| Brazil nuts | 1 oz (~500 mg phytic acid) | — |
| Pinto beans, cooked | ½ cup (~300 mg phytic acid) | — |
| Walnuts | 1 oz (~300 mg phytic acid) | — |
| Oats, rolled | ½ cup (~450 mg phytic acid) | — |
Wheat bran
- Amount
- 1 oz (~700 mg phytic acid)
- %DV
- —
Almonds, raw
- Amount
- 1 oz (~400 mg phytic acid)
- %DV
- —
Sesame seeds
- Amount
- 1 oz (~1,400 mg phytic acid)
- %DV
- —
Soybeans, dry
- Amount
- ½ cup (~1,000 mg phytic acid)
- %DV
- —
Brazil nuts
- Amount
- 1 oz (~500 mg phytic acid)
- %DV
- —
Pinto beans, cooked
- Amount
- ½ cup (~300 mg phytic acid)
- %DV
- —
Walnuts
- Amount
- 1 oz (~300 mg phytic acid)
- %DV
- —
Oats, rolled
- Amount
- ½ cup (~450 mg phytic acid)
- %DV
- —
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is phytate good or bad?⌄
Both. As a supplement at a specific time it may provide antioxidant benefits. In food eaten alongside iron-rich meals, it reduces mineral absorption - relevant if you're at risk for iron deficiency.
Should I take this with food?⌄
No - take it on an empty stomach to avoid binding minerals from food.
References by claim
Calcium-oxalate kidney stone prevention
Antioxidant / cellular protection (mechanism)
Cancer chemoprevention
Shamsuddin, 2002 — Journal of Nutrition (2002) link
Iron overload (hereditary hemochromatosis, transfusion overload)
Schlemmer et al., 2009 — PubMed — Molecular Nutrition & Food Research (2009) link
Track Calcium magnesium phytate with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.